Acetylsalicylic acid resistance in patients with Type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease

Mustafa Cetin¹, Emrullah Kiziltunc², Zehra Guven Cetin³, Hulya Cicekcioglu⁴, Muslum Sahin⁵, Serhat Isik⁶, Alparslan Kurtul⁷, Ender Ornek⁸, Feridun Vasfi Ulusoy⁹

ABSTRACT

Objective: Several studies have demonstrated the beneficial role of antiplatelet therapy with acetylsalicylic acid (ASA) at atherosclerotic vascular disease. Antiaggregant effect of ASA is not uniform in all patients. Purpose of the present study is to evaluate the prevalence of ASA resistance in patients with type 2 diabetes mellitus (T2DM), pre-diabetes and non-diabetic coronary artery disease (CAD).

Methods: Effect of ASA was assessed using the platelet function analyzer (PFA-100) system. Resistance to ASA was defined as a normal collagen/epinephrine induced closure time after one week of ASA therapy. Patients with non-diabetic CAD, pre-diabetes and T2DM were compared.

Results: ASA resistance was found in 26 (37.1%), 6 (17.6%) and 41 (26.5%) patients in the groups, respectively (p=0.154). ASA resistance was found to be significantly higher in men, smokers and insulin users, besides this it was found to be significantly lower in beta blocker (BB) users, angiotensin converting enzyme inhibitor (ACEI) users with univariate analysis. However insulin usage was found to be the single effective parameter on ASA resistance in multivariate analysis.

Conclusion: There was no difference with regard to ASA resistance between groups. While ASA resistance was higher in men, smokers and insulin users, it was lower in patients using BBS and ACEIs.

KEY WORDS: Acetylsalicylic acid resistance, Coronary artery disease, Diabetes mellitus.

How to cite this:

Cetin M, Kiziltunc E, Cetin ZG, Cicekcioglu H, Sahin M, Isik S, et al. Acetylsalicylic acid resistance in patients with Type 2 diabetes mellitus, prediabetes & non-diabetic coronary artery disease. Pak J Med Sci 2014;30(3):539-544.
doi: http://dx.doi.org/10.12669/pjms.303.4773

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Mustafa Cetin, MD,
2. Emrullah Kiziltunc, MD,
3. Zehra Guven Cetin, MD,
4. Hulya Cicekcioglu, MD,
5. Muslum Sahin MD,
6. Serhat Isik, MD,
7. Alparslan Kurtul, MD;
8. Dept. of Cardiology, Ankara Education and Research Hospital, Sükriye Mahallesi, Ulucanlar Caddesi, 06340, Ankara, Turkey.
9. Ender Ornek,
10. Associate Professor,
11. Feridun Vasfi Ulusoy, MD,
12. Department of Cardiology, 1-5,8,9: Department of Cardiology, 1-6,8,9: Ankara Numune Education and Research Hospital, Talatpasa Bulvari, 06100, Sihhiye, Ankara, Turkey.

Correspondence:
Emrullah Kiziltunc,
Ankara Numune Education & Research Hospital, Cardiology Department, 06230, Ankara, Turkey.
E-mail: e.kiziltunc@gmail.com

* Received for Publication: December 21, 2013
* Accepted for Publication: * February 26, 2014

INTRODUCTION

Acetylsalicylic acid reduces the risk of cardiovascular events in a wide range of patients with established cardiovascular disease (CVD).¹ Type 2 diabetes is associated with a 2-3 fold increased risk of CVD which is the leading cause of mortality and morbidity.² Clinical guidelines recommend use of ASA for secondary prevention in type 2 diabetic patients with a history of CVD.³

Despite therapeutic benefits of ASA, its antiplatelet effect is not uniform in all patients and platelet aggregation studies have shown that 5,5–60% of patients appear to be unresponsive to the antiplatelet effect of ASA.⁴ These patients are clinically referred as ASA-resistant or ASA non-responders. Acetylsalicylic acid resistance has been
associated with an increased risk of thrombotic and embolic cardiovascular events compared to patients who are ASA-sensitive.5,6

Hereby, we aimed to compare the frequency of ASA resistance between patients with diabetes mellitus type 2 (T2DM), pre-diabetic patients and non-diabetic coronary artery disease (CAD) patients, and to bring into light the factors that may be related to ASA resistance.

METHODS

Study design: The study protocol was approved by local ethics committee of Ankara Numune Education and Research Hospital and was conducted in accordance with the Declaration of Helsinki. The effect of ASA was assessed using the platelet function analyzer (PFA-100) system. Patients with abnormal blood count results, those with hepatic and renal disease, and those taking drugs that affect the platelet function were excluded from the study. Resistance to ASA was defined as a normal collagen/epinephrine induced closure time (CTCEPI) (82–165 s) after one week of ASA therapy. Three age- and sex-matched groups including the non-diabetic CAD (group 1, n=70), pre-diabetes (group 2, n=34) and T2DM (group 3, n=155) were compared. We determined pre diabetes as impaired fasting glucose and impaired glucose intolerance.

Laboratory Assays:

PFA-100: The PFA-100 is an automated test system which simulates platelet-based hemostasis in vitro. The test cartridge simulates an injured blood vessel and measures the time required to form a platelet plug [defined as closure time (CT)] which occludes a microscopic aperture cut into a collagen/epinephrine- or collagen/ADP-coated membrane under high shear flow condition.7

The collagen/epinephrine cartridge is the primary cartridge for detection of the aspirin effect on platelet aggregation. All the blood samples were tested according to the manufacturer’s instruction not earlier than 30 minutes and within two hours of blood sampling. Previous studies8 have shown that there is no statistically significant effect of blood sample storage on CT measurements for up to 4 hours. The maximal CT for collagen/epinephrine cartridges is 300 s and values greater than 300 s were reported as non-closure. In these cases, a value of 301 s was assigned for statistical calculations.

Statistical Analysis: Analysis of the data was performed using the Statistical Package for Social Sciences (SPSS) version 13.0 software (SPSS Inc., Chicago, IL, United States). The metric discrete variables were shown as mean ± standard deviation, and percentages were used for the categorical variables. The chi-square tests were used to assess the statistical significance of the differences between the groups in the frequency distribution of categorical variables, unless the expected cell size was less than five, in which case the Fisher’s exact test was used. The medians were compared using the Mann Whitney U test when the number of independent groups was two. The differences between the medians of more than two groups were evaluated using the Kruskal Wallis test. Univariate and multivariate regression analysis were used for estimating the relationship among variables. A p value of less than 0.05 was considered statistically significant.

RESULTS

The baseline characteristics of groups are shown in Table-I. ASA resistance was found to be similar between groups (p=0.154) (Fig.1). CTCEPI values were also non significant between the groups (219.7±79.9 s, 252.1±60.9 s, 234.7±71.6 s respectively, p=0.121). When the cases with ASA resistance were compared with cases without ASA resistance, no significant differences were encountered with regard to age, duration of T2DM, glycemic and lipid parameters, hCRP, Htc, platelet number, uric acid, fibrinogen and microalbumin. The rate of males in the ASA resistance cases was found to be higher than that in the ASA sensitive cases (58.7 vs 45.6%, p=0.047).

The smoking status and the frequency of hyperlipidemia (HPL) in the ASA resistance cases were higher than those of the non-resistant cases (35.1% vs 26.9%, p=0.025; 68.4% vs 55.0, p=0.037).

Fig.1: ASA resistance of groups.
Group 1: Patients with Coronary Artery Disease; Group 2: Prediabetic Patients; Group 3: Diabetic Patients.
While ASA resistance was more frequent in those taking insulin (50.0% vs 23.6%, p=0.012) than in those not taking insulin, patients using beta blockers and angiotensin converting enzyme inhibitors (ACEI) had significantly lower ASA resistance (48.3% vs 57.3%, p=0.035; 27.6% vs 37.4%, p=0.029) (Table-II). The mean CTCEPI value in patients taking insulin was 204.4±70.4, and this value in patients not taking insulin was 250.0±63.9 (p=0.002). The effect of insulin use on ASA resistance was seen to continue in multivariate regression analysis. (Table-III).

**DISCUSSION**

In the present study we found that there is no difference between groups of diabetic patients, prediabetic patients and non-diabetic coronary artery disease patients with regard to ASA resistance. There are some studies comparing ASA resistance between diabetic and coronary heart disease patients, but to our knowledge there is no study evaluating ASA resistance in pre-diabetic patients. The findings of studies assessing ASA resistance in patients with diabetes mellitus or cardiovascular disease prove confusing results. Abaci et al. found that diabetic patients had less ASA resistance than patients with coronary artery disease.5 Primary Prevention Project study showed that non-diabetic patients have a 41% decrease in heart disease-related death with 100 mg/day ASA versus 10% in diabetic patients.9 The writers concluded that low decrease of end-points at diabetic group might in part be due to ASA resistance. These two studies are contrary examples for ASA resistance in diabetic patients. In our study we could not found any difference between diabetic, prediabetic and non-diabetic coronary artery patients with respect to ASA resistance. Another study had similar findings like ours that there was no relationship between ASA resistance and presence of diabetes in stroke patients.10

In this study, while there was ASA resistance in 43.3% of patients taking insulin, there was ASA resistance in 19.1% of those not taking insulin. It is known that diabetic patients have high platelet reactivity.11 Although insulin suppresses P2Y12-mediated platelet aggregation in healthy subjects,12 it is known that if there is insulin resistance such as DM accompanying central obesity, obesity and HT, there is unresponsiveness to the antiaggregant effect of insulin.12-14 In our study, patients who use insulin had significantly higher levels of HbA1c and hCRP levels, higher microalbuminuria, longer mean duration of DM and higher values of fasting glucose, post-prandial glucose. These findings give

| Variables                        | Group 1 (n=70) | Group 2 (n=34) | Group 3 (n=155) | p   |
|----------------------------------|---------------|----------------|----------------|-----|
| Age, years                       | 57.0±7.6      | 55.0±10.7      | 54.5±9.0       | 0.157|
| Gender (M/F)                     | 28/42         | 14/20          | 63/92          | 0.599|
| BMI                              | 29.4±6.4      | 31.0±4.7       | 30.6±5.4       | 0.312|
| Fasting glucose, mg/dl           | 85.5±8.4      | 101.0±16.2     | 163.5±70.0     | <0.001|
| Postprandial glucose, mg/dl      | 98.7±15.2     | 129.2±29.1     | 230.1±95.7     | <0.001|
| HbA1c, %                         | 5.6±0.4       | 6.2±0.8        | 8.9±2.4        | <0.001|
| TC, mg/dl                        | 172.2±42.4    | 179.4±51.4     | 182.4±54.0     | 0.404|
| TG, mg/dl                        | 146.4±93.5    | 125.4±70.7     | 166.1±159.3    | 0.288|
| HDL-C, mg/dl                     | 36.5±9.6      | 41.9±9.5       | 40.4±10.5      | 0.015|
| LDL-C, mg/dl                     | 105.9±34.1    | 124.0±44.5     | 112.5±41.7     | 0.131|
| Htc, %                           | 43.5±4.0      | 40.0±4.2       | 41.2±5.1       | 0.001|
| Plt, x1000/mm$^3$                | 276.3±31.2    | 267.3±63.9     | 258.3±94.0     | 0.849|
| Uric acid, mg/dl                 | 5.8±1.7       | 4.7±1.4        | 4.8±1.3        | <0.001|
| hCRP, mg/dl                      | 2.3±2.4       | 2.0±1.8        | 3.6±3.5        | 0.013|
| Hcy, µmol/L                      | 18.1±9.7      | 12.6±4.6       | 12.4±6.2       | <0.001|
| Fibrinogen, mg/dl                | 349.2±67.8    | 338.5±60.8     | 370.5±84.0     | 0.696|
| Microalbumin, mg/24 hour         | 3.5±5.5       | 9.5±10.2       | 67.2±274.5     | 0.158|
| CTCEPI, s                        | 219.7±79.9    | 252.1±60.9     | 234.7±71.6     | 0.121|
us that patients using insulin have a higher degree of disease status and inflammatory status. These higher levels of inflammation and hyperglycemia indicators make one think that the reduced sensitivity to aspirin in T2DM may be related to hyperglycaemia or to the associated inflammation.\textsuperscript{15}

In a study, a correlation between \textit{in vitro} TxB2 production and systemic levels of fasting glucose or HbA1c was demonstrated.\textsuperscript{16} The reduced inhibitory action of aspirin on platelet COX-1 may be attributed either to the glycation-induced conformational changes of the platelet membranes with resulting impaired aspirin entrance, and/or to a less-efficient acetylation previously demonstrated in platelets re-suspended in high glucose medium.\textsuperscript{17,18}

In our study, ASA resistance was detected lower in patients taking beta blocker and ACE-I. In a study, patients with effective platelet inhibition were found to be more frequent users of beta-adrenoceptor antagonists and ACE inhibitors, whereas patients with ineffective platelet inhibition were found to be more frequent users of statins.\textsuperscript{19}

### Table II: Comparison of the demographic and laboratory parameters between those with ASA resistance and those without.

| Variables                  | ASA resistance + (n=73) | ASA resistance - (n=186) | P   |
|----------------------------|------------------------|-------------------------|-----|
| Age, years                 | 56.0±7.4               | 54.8±9.5                | 0.492 |
| DM duration, years         | 9.4±6.5                | 7.4±6.5                 | 0.976 |
| Fasting glucose, mg/dl     | 125.6±66.4             | 132.8±64.5              | 0.144 |
| Postprandial glucose, mg/dl| 197.2±73.6             | 196.4±91.4              | 0.748 |
| HbA1c, %                   | 8.7±1.8                | 8.7±2.7                 | 0.976 |
| TC, mg/dl                  | 181.2±47.5             | 178.6±49.6              | 0.888 |
| TG, mg/dl                  | 159.3±121.1            | 158.5±150.0             | 0.950 |
| HDL-C, mg/dl               | 39.3±10.5              | 39.0±9.4                | 0.907 |
| LDL-C, mg/dl               | 112.3±39.9             | 111.9±39.3              | 0.701 |
| Hb, g/dl                   | 14.2±1.6               | 14.1±1.6                | 0.568 |
| Plt, x1000/mm\textsuperscript{3} | 247.2±94.0         | 252.9±83.7              | 0.088 |
| Htc, %                     | 41.5±4.5               | 42.0±5.2                | 0.239 |
| MPV, fl                    | 9.0±0.9                | 8.7±0.9                 | 0.226 |
| Uric acid, mg/dl           | 5.4±1.6                | 5.0±1.6                 | 0.273 |
| hCRP, mg/dl                | 3.3±3.6                | 2.6±2.7                 | 0.504 |
| Hcy, μmol/L                | 16.0±10.2              | 14.3±7.1                | 0.195 |
| Fibrinogen, mg/dl          | 359.1±74.2             | 356.3±78.1              | 0.864 |
| Microalbumin, mg/24 hour   | 8.6                    | 9.6                     | 0.855 |
| Male Gender (%)            | 58.7                   | 45.6                    | 0.047 |
| Smoking, %                 | 35.1                   | 26.9                    | 0.025 |
| HT, %                      | 64.9                   | 59.7                    | 0.500 |
| HPL, %                     | 68.4                   | 55.0                    | 0.037 |
| Insulin, %                 | 50.0                   | 23.6                    | 0.012 |
| MET, %                     | 46.2                   | 51.4                    | 0.647 |
| SU, %                      | 26.9                   | 30.6                    | 0.728 |
| TZD, %                     | 7.7                    | 5.6                     | 0.697 |
| Beta blocker, %            | 48.3                   | 57.3                    | 0.035 |
| ACEI, %                    | 27.6                   | 37.4                    | 0.029 |
| ARB, %                     | 34.5                   | 26.9                    | 0.293 |
| CCB, %                     | 12.1                   | 16.2                    | 0.467 |
| Statin, %                  | 47.4                   | 43.8                    | 0.656 |

DM: diabetes mellitus; Hb: hemoglobin; HbA1c: glycosylated hemoglobin; hCRP: high-sensitivity C-reactive protein; Hcy: homocysteine; HDL-C: high density lipoprotein – cholesterol; Htc: haematocrit; LDL-C: low density lipoprotein-cholesterol; MPV: mean platelet volume; Plt: platelets; TC: total cholesterol; TG: triglyceride; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blockers; HT: hypertension; MET: metformin; SU: sulfonylurea; TZD: thiazolidinediones.
The effects of beta-adrenergic antagonists on collagen and epinephrine-induced platelet aggregation suggest an additive effect of these drugs with respect to antiplatelet therapy. A study has reported that the benefits of ASA and ACE inhibitors may be attenuated when both agents are used together, but another study has showed no significant effect of ACEI on platelet aggregation on the logistic regression analysis.

We found that smokers have significantly higher ASA resistance. We know that smoking generates a prothrombotic state both with acute usage and long term smoking. Recurrent stimulation of platelets by smoking may explain the ASA resistance in smokers. Eskandarian et al. demonstrated smoking as a risk factor for ASA resistance at chronic stable angina patients.

There is confusing findings about ASA resistance and gender. While some studies demonstrate higher ASA resistance with male gender, some demonstrate female gender. We found ASA resistance higher at men in our study. There are arguments that hyperlipidaemia can cause ASA resistance. Friend et al. found ASA resistance was significantly higher in patients with hyperlipidaemia, they also showed the relationship with total cholesterol levels, LDL levels with ASA resistance. In our study we find hyperlipidaemia was significantly higher in ASA resistance cases; but we could not found any relationship with lipid subfractions.

CONCLUSION

We could not find any difference between diabetic, pre-diabetic and non-diabetic coronary artery disease patients with regard to ASA resistance. ASA resistance was determined to be low in patients taking beta blockers and ACE-I than in those not taking these drugs, and higher in those taking insulin, men, and smokers. ASA resistance predictors and related situations should be well defined with larger trials because it is known that ASA resistance increases cardiovascular mortality.

Conflict of Interest, funds, support: None declared.

REFERENCES

1. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308(6921):81-106.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-444.
3. American Diabetes Association. Standards of Medical Care in Diabetes-2013. Diabetes Care. 2013;36(Suppl 1):11-66.
4. Muir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart. 2009;95:1225-1229.
5. Vejar M, Fragasso G, Hackett D, Lipkin DP, Maseri A, Born GV. Dissociation of platelet activation & spontaneous myocardial ischemia in unstable angina. Thromb Haemost. 1990;63:163–168.
6. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–965.
7. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24:195–202.
8. Abaci A, Caliskan M, Bayram F, Yilmaz Y, Cetin M, Unal A. A new definition of aspirin non-responsiveness by platelet function analyzer-100 & its predictors. Platelets. 2006;17:7-13.
9. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. PPP Collaborative Group: Primary prevention of cardiovascular events with low-dose aspirin & vitamin E in type 2 diabetic patients. Diabetes Care. 2003;26;3264 –3272.
10. Sobol AB, Selmaj K, Mochecka A, Kumor A, Loba J. Aspirin Responsiveness in Ischemic Stroke Patients in Relation to Diabetes Mellitus, Lipid & Hemostatic Profile. Adv Clin Exp Med. 2010;19(5):593–599.
11. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost. 2004;2:1282–1291.
12. Ferreira IA, Mocking AI, Feijge MA, Gorter G, van Haften TW, Heemskerk JW, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2006;26(2):417-422.
13. Anfossi G, Russo I, Trovati M. Platelet resistance to the anti-aggregating agents in the insulin resistant states. Curr Diabetes Rev. 2006;2:409-430.
14. Trovati M, Mularoni EM, Burzacca S, Ponzi MC, Massucco P, Mattiello L, et al. Impaired insulin-induced platelet antiaggregating effect in obese & in obese NIDDM patients. Diabetes. 1995;44:1318-1322.
15. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res. 2004;113:101-113.
16. Pulcinelli FM, Biasucci LM, Rondinone S, Giubilato S, Leo A, Di Renzo L. COX-1 sensitivity & thromboxane A2 production in type 1 & type 2 diabetic patients under chronic aspirin treatment. Eur Heart J. 2009;30:1279-1286.
17. Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation & reduced sensitivity of blood platelets to aspirin. J Mol Med. 2005;83:148-158.
18. Winocour PD, Watala C, Perry DW, Kinlough-Rathbone RL. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost. 1992;68:577-582.
19. Feher G, Koltai K, Papp E, Alkonyi B, Solyom A, Kenyeres P. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications & haemorrhheological variables. Drugs Aging. 2006;23:559-567.
20. Abaci A, Yilmaz Y, Caliskan M, Bayram F, Cetin M, Unal A. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes. Thromb Res. 2005;116:465-470.
21. Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK. Prevalence & risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. Am J Neuroradiol. 2008;29:281-285.
22. Blanche D. Involvement of hydrogen & lipid peroxides in acute tobacco smoking-induced platelet hyperactivity. Am J Physiol. 1995;268:679-685.
23. Ichiki K, Ikeda H, Haramaki N, Ueno T, Imaizumi T. Long-term smoking impairs platelet-derived nitric oxide release. Circulation. 1996;94:3109-3114.
24. Eskandarian R, Darabian M, Heshmatnia J, Ghorbani R. Acetyl salicylic acid resistance in patients with chronicstable angina & the correlation with coronary risk factors. Saudi Med J. 2012;33(1):39-43.
25. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med. 2005;118(7):723-727.
26. Friend M, Vucenik I, Miller M. Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ. 2003;326:82-83.